Biologics Pharmacy Dispenser Workload Report

Dispenser	Project Rea	gent	Count		
GIFFOKA					
	ANTI IL-12 (B	ANTI IL-12 (BD ILS999)			
	C ²	17.8 ra IgG2a WT	6		
	IL	-12 hu	4		
	J6	95	5		
	J6	95 F(ab)	1		
	J6	95 F(ab')2	1		
	R2	2-10F6 ra IgG2b wt	1		
	ANTI IL-18 M	ANTI IL-18 MAB			
	12	25-2H mu lgG1	2		
	10	C5 mu IgG2a/k wt	2		
	2.	5(E)mg1	1		
	2.	5(E)wg1	1		
	ANTI-IL-12 (B	ANTI-IL-12 (BACKUP)			
	10	04.7 hu IgG1 mut (234 235)/K	7		
	10	04.7 hu lgG1 mut (234 235)/K-FITC	1		
	C	340 hu IgG1/K wt	6		
	C	3.6.2 mu lgG1 WT	3		
	Hu	u IgG1/K (Chemicon)	1		
	Hu	u IgG1/K (Chemicon)-FITC	1		
	Ye	61 hu lgG1/L	1		
	ANTI-RAGE M	1AB			
	M	L37-7F9	1		
	ANTI-TNF AL	PHA			
	hu	ı TNFalpha-BIOTIN	1		
	CD19				
	TA	ACI mlgG2a fusion	1		
	Y 1	13-238	2		
	CXCL13				
	hu	ı CXCL13/BLC/BCA-1	2		
	m	u CXCL13/BLC/BCA-1	4		
	X\	N25-2C4-4H8 Mu IgG1/K wt	4		
	X\	N25-6A2-2F10 Mu lgG1/k wt	2		
	IMMUNOSCIEI	NCE EXPLORATORY			
	Re	ecombinant Human IL-23	4		
	Re	ecombinant Murine IL-23	12		
	K-5 ABT-828	3			

Tuesday, June 13, 2006 Page 1 of 3

Dispenser	Project	Reagent	Count		
		SZ39-12D12.3G1	2		
			79		
HUELSRM					
	ANTI IL-	1 ALPHA/BETA			
	1B7.11 mu lgG1				
	ANTI IL-13				
		11B11.2D2	1		
		CAT354 hu IgG4/L	3		
		EB26-5G1.3E3	2		
		Recombinant Human IL-13 Wt (213-IL/	7		
		Recombinant mu IL-13Ra2/Fc Chimera	a 2		
		SZ26-13C5.1A9	7		
		SZ26-9C11.3F6.3B12	6		
		SZ43-51D9.3B11.3F1	2		
		SZ45-48D3.3E6.5C7	1		
	ANTI-NG	R MAB			
		ML28-5H5-5H11-2A6	1		
	ANTI-TN	F ALPHA			
		8C11-1E10	2		
		D2E7	1		
		hu TNF-alpha	1		
	CD19				
		TACI mlgG2a fusion	1		
	CXCL13				
		mu CXCL13/BLC/BCA-1	4		
		XW25-2C4-4H8 Mu IgG1/K wt	1		
		XW25-6A2-2F10 Mu lgG1/k wt	2		
	GLP1R A	GONIST			
		EB19.9A10.5A9 mu lgG1/K	2		
	K-5 ABT	-828			
		SZ39-12D12.3G1	1		
			49		
INVADMIN					
	ANTI-TN	F ALPHA			
		Remicade (Infliximab)	1		
			1		
PEREILX					
	ANTI IL-	1 ALPHA/BETA			
		1B7.11 mu lgG1	2		
		4G2.H11 mu lgG1/K wt	2		

Tuesday, June 13, 2006 Page 2 of 3

Dispenser	Project	Reagent	Count
		9H10.C2.E2 mu lgG1/K wt	3
	recombinant hIL-1a		1
		recombinant mIL-1 alpha	2
		recombinant mIL-1 beta	2
	ANTI IL-18 MAB		
		125-2H mu lgG1	1
		1C5 mu IgG2a/k wt	1
	ANTI-TN	F ALPHA	
		8C11-1E10	13
		8C11-1E10 F(ab')2	1
		D2E7	5
		D2E7 F(ab¿)2	1
		Enbrel (Etanercept)	5
		Enbrel (Etanercept) F(ab)¿2	1
		hu IgG1/K	2
		hu TNF-alpha	1
		MAB210 mu IgG1/K wt	1
		mu TNF-a	1
		murine TNFa-biotin	1
		Remicade (Infliximab)	2
		Remicade (Infliximab) F(ab)¿2	1
	CXCL13		
		XW25-2C4-4H8 Mu IgG1/K wt	1
		XW25-6A2-2F10 Mu IgG1/k wt	1
	DVD-IG		
		Mu DVD4-Ig	2
	GLP1R AGONIST		
		EB19.5A10.1D4 mu lgG2a/K	1
		SZ5-2A9.3B4.4E11 mu lgG1/K	1
	IMMUNO	SCIENCE EXPLORATORY	
		Recombinant Murine IL-23	1
			56
SWENSJT			
	ANTI-TN		
		8C11-1E10	1
		murine TNFa-biotin	1
	CXCL13		
		XW25-2C4-4H8 Mu IgG1/K wt	1
		XW25-6A2-2F10 Mu lgG1/k wt	1
	-		4

Tuesday, June 13, 2006 Page 3 of 3